Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697832 | Clinical Oncology | 2017 | 8 Pages |
Abstract
Seventy per cent of patients treated with first-line systemic therapy for recurrent/metastatic cervical cancer subsequently received second-line treatment but response rates were poor. There remains no standard of care for second-line systemic therapy for advanced cervical cancer. Patients should be considered for clinical trials whenever feasible, including novel targeted agents and immunotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. McLachlan, S. Boussios, A. Okines, D. Glaessgen, S. Bodlar, R. Kalaitzaki, A. Taylor, S. Lalondrelle, M. Gore, S. Kaye, S. Banerjee,